News
FDA asks Sarepta to stop shipping gene therapy
Digest more
A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results